Sustainability in Pharma – Sourcing Eco-Friendly Excipients

Generic drug producers in emerging markets are under the same pressures as face the pharmaceutical industry globally to align production practices with United Nations sustainability goals.

These goals impact almost every part of the pharma value chain from resource and energy-intensive manufacturing processes to the challenges of reducing plastic packaging waste and environmental pollution from active substances and solvents.

Building green supply chains

For medium-sized producers, the major upstream challenge is in sustainable sourcing of excipients and fine chemicals from environmentally audited producers.

Polypharma GmbH, recognizes the critical role that responsible sourcing plays in building a green pharma supply chain. Its portfolio of eco-friendly drug formulation dossiers and suggested ingredient sources have sustainability in mind. This supports emerging generics producers in reducing their carbon footprint while maintaining the highest standards of quality and compliance.

Meeting global standards

Polypharma can locate sustainable excipient and suppliers that not only support product performance but also comply with stringent global sustainability regulations, including EU Green Deal initiatives and international GMP guidelines. From sourcing renewable raw materials to implementing circular economy practices, Polypharma is  committed to driving meaningful change throughout the supply chain.

It can also show partners how to join forward-thinking companies in adopting use cutting-edge technologies like digital twins and AI-powered analytics to monitor and optimize every stage of production, aiming for net-zero pharma targets. These tools enable real-time carbon footprint tracking, predictive maintenance, and smarter sourcing decisions, transforming sustainability from a marketing promise into measurable action.

For example, AI Automated Compliance Monitoring can help navigate the increasingly complex and evolving global regulatory landscape, including US FDA, EMA, and CDSCO, by aggregating API supplier status, audit records, and warning letters in an audit trail to ensure production pipelines contain only compliant and up-to-date suppliers, thus enhancing GMP compliance and minimizing regulatory delays, as well as safeguarding sustainability.

Polypharma actively supports partners in this transformation by integrating digital tools and transparent data reporting into its own processes, ensuring that sustainability strategies deliver tangible results.

The Business Case for Sustainable Sourcing

In an era where patients, regulators, and partners increasingly demand environmentally responsible pharma products, sourcing eco-friendly excipients is becoming a strategic necessity for generic drug producers, for at least six reasons:

1. Competitive Differentiation: while generic drugs compete largely on cost, sustainability provides a new added value layer that can please consumers and buyers and provide a competitive edge in tendering for contracts and B2B deals.
2. Easier Compliance & Market Access: Sourcing sustainably helps producers stay ahead of evolving regulations, which are tightening globally with the EU Green Deal, US FDA sustainability initiatives, and local environmental standards in LATAM, Africa, and Asia. This can avoid later supply disruptions and costly reformulation.
3. Supply Chain Transparency: This can build trust for global buyers, including large pharma, who increasingly require transparency about the environmental impacts over the whole supply chain, as well as more comprehensive traceability and ESG reporting.
4. Operational Efficiency & Cost Savings: Suppliers using greener processes often deploy energy-efficient production, recycling, and waste reduction, leading to lower energy costs, reduced waste disposal expenses and less risk of environmental fines or shutdowns.
5. Stronger Brand & Investor Appeal: Even in cost-sensitive markets, investors and strategic partners favor companies with robust sustainability strategies. Enhancing the producer’s sustainability credentials can attract ESG-focused investors and global partners.
6. Future-Proofing Product Portfolios: Formulating generics with sustainable excipients and APIs makes it easier to pivot into regulated markets, meet new customer and regulator sustainability KPIs, and participate in green procurement programs and public sector contracts.

Polypharma recognizes that for generic drug producers in emerging markets, sourcing sustainable ingredients is not just an ethical issue but is also about securing market access, reducing operational risks, saving costs long term, and becoming a supplier of choice globally.

Resources

Click on Polypharma Service Request to request a free consultation with Polypharma’s sustainability experts on building a greener supply chain.
Click on Subscribe to Polypharma newsletter for exclusive eco-pharma strategies tailored to businesses in emerging markets.